Cargando…

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

In the RV144 trial, vaccine-induced V1V2 IgG correlated with decreased HIV-1 risk. We investigated circulating antibody specificities in two phase 1 poxvirus prime-protein boost clinical trials conducted in South Africa: HVTN 097 (subtype B/E) and HVTN 100 (subtype C). With cross-subtype peptide mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Xiaoying, Laher, Fatima, Moodie, Zoe, McMillan, Arthur S., Spreng, Rachel L., Gilbert, Peter B., Huang, Ying, Yates, Nicole L., Grunenberg, Nicole, Juliana McElrath, M., Allen, Mary, Pensiero, Michael, Mehra, Vijay L., Der Meeren, Olivier Van, Barnett, Susan W., Phogat, Sanjay, Gray, Glenda E., Bekker, Linda-Gail, Corey, Lawrence, Tomaras, Georgia D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005751/ https://www.ncbi.nlm.nih.gov/pubmed/32034163 http://dx.doi.org/10.1038/s41598-020-57491-z

Ejemplares similares

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
por: Fisher, Leigh, et al.
Publicado: (2019)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

The Evolution of Poxvirus Vaccines
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2015)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

A safer poxvirus vaccine
por: Bashyam, Hema
Publicado: (2008)

Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine
por: Chiuppesi, Flavia, et al.
Publicado: (2020)

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
por: Lazarus, Erica Maxine, et al.
Publicado: (2014)

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans
por: Xu, Shiwei, et al.
Publicado: (2022)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Recombinant poxvirus vaccines in biomedical research
por: Schnierle, Barbara S., et al.
Publicado: (2007)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Review of preventative HIV vaccine clinical trials in South Africa
por: Laher, Fatima, et al.
Publicado: (2020)

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
por: Kaufman, Howard L, et al.
Publicado: (2007)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Immunogenicity of poxvirus-based vaccines against Nipah virus
por: Medina-Magües, Emily S., et al.
Publicado: (2023)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Poxvirus tropism
por: McFadden, Grant
Publicado: (2005)

Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform
por: Chiuppesi, Flavia, et al.
Publicado: (2020)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
por: Zhao, Lue Ping, et al.
Publicado: (2020)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa
por: Mashingaidze, Rujeko, et al.
Publicado: (2023)

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
por: Chiuppesi, Flavia, et al.
Publicado: (2020)

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
por: Stamatatos, Leonidas, et al.
Publicado: (2021)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
por: Huang, Yunda, et al.
Publicado: (2022)

Vaccination establishes clonal relatives of germinal center T cells in the blood of humans
por: Heit, Antje, et al.
Publicado: (2017)

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials
por: Fiore-Gartland, Andrew, et al.
Publicado: (2016)

Chicken Embryonic-Stem Cells Are Permissive to Poxvirus Recombinant Vaccine Vectors
por: Giotis, Efstathios S., et al.
Publicado: (2019)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses
por: Hancock, Gemma, et al.
Publicado: (2015)

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap
por: Gray, Glenda E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k7io8jidlp4m4hhjh6etp7j73u